4547.T
4547.T
JP3240600001
KISSEI PHARMACEUTICAL CO
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 85/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±27.3% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (-0.1x).

Beta (Market Relation)
-0.14x
Defensive
Volatility (5Y p.a.)
27.3% p.a.
5-Year Horizon
Max Drawdown (5Y)
-28.0%
5-Year Horizon
Sharpe Ratio
0.23
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -13.4%
3 Years 27.6% -28.0% 0.05 +3.9%
5 Years 27.3% -28.0% 0.23 +9%
10 Years 27.7% -43.5% 0.02 +3.1%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
10 ISS Score: 10 / 10
Audit Risk
1 ISS Score: 1 / 10
Board Risk
10 ISS Score: 10 / 10
Short Ratio
-
ende